These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22061180)

  • 1. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
    Sergott RC; Westall CA
    Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding and interpreting vision safety issues with vigabatrin therapy.
    Plant GT; Sergott RC
    Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.
    Krauss G; Faught E; Foroozan R; Pellock JM; Sergott RC; Shields WD; Ziemann A; Dribinsky Y; Lee D; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Mar; 56():15-9. PubMed ID: 26807550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
    Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA
    Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Registry initiated to characterize vision loss associated with vigabatrin therapy.
    Pellock JM; Faught E; Sergott RC; Shields WD; Burkhart GA; Krauss GL; Foroozan R; Wesche DL; Weinberg MA
    Epilepsy Behav; 2011 Dec; 22(4):710-7. PubMed ID: 21978471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vigabatrin: 2008 update.
    Willmore LJ; Abelson MB; Ben-Menachem E; Pellock JM; Shields WD
    Epilepsia; 2009 Feb; 50(2):163-73. PubMed ID: 19230067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
    Sergott RC; Bittman RM; Christen EM; Sagar SM
    Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
    Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
    Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
    Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG
    Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
    Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.
    Ruether K; Pung T; Kellner U; Schmitz B; Hartmann C; Seeliger M
    Arch Ophthalmol; 1998 Jun; 116(6):817-9. PubMed ID: 9639460
    [No Abstract]   [Full Text] [Related]  

  • 14. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
    Riikonen R; Rener-Primec Z; Carmant L; Dorofeeva M; Hollody K; Szabo I; Krajnc BS; Wohlrab G; Sorri I
    Dev Med Child Neurol; 2015 Jan; 57(1):60-7. PubMed ID: 25145415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring field loss in children administered vigabatrin: a problem in search of a solution.
    Good WV
    J AAPOS; 2011 Oct; 15(5):411-2. PubMed ID: 22108349
    [No Abstract]   [Full Text] [Related]  

  • 16. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infantile spasms and vigabatrin. Visual field defects may be permanent.
    Lhatoo SD; Sander JW
    BMJ; 1999 Jan; 318(7175):57. PubMed ID: 10068225
    [No Abstract]   [Full Text] [Related]  

  • 18. Vigabatrin for infantile spasms.
    Pesaturo KA; Spooner LM; Belliveau P
    Pharmacotherapy; 2011 Mar; 31(3):298-311. PubMed ID: 21361740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
    Camposano SE; Major P; Halpern E; Thiele EA
    Epilepsia; 2008 Jul; 49(7):1186-91. PubMed ID: 18479386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vigabatrin-associated visual field loss.
    Fecarotta C; Sergott RC
    Int Ophthalmol Clin; 2012; 52(3):87-94, xii. PubMed ID: 22668542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.